Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

103 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Erondu N, et al. Among authors: kaufman kd. Cell Metab. 2006 Oct;4(4):275-82. doi: 10.1016/j.cmet.2006.08.002. Cell Metab. 2006. PMID: 17011500 Clinical Trial.
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB. Erondu N, et al. Among authors: kaufman kd. Obesity (Silver Spring). 2007 Aug;15(8):2027-42. doi: 10.1038/oby.2007.242. Obesity (Silver Spring). 2007. PMID: 17712121 Clinical Trial.
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR. Green JB, et al. Among authors: kaufman kd. Am Heart J. 2013 Dec;166(6):983-989.e7. doi: 10.1016/j.ahj.2013.09.003. Epub 2013 Oct 23. Am Heart J. 2013. PMID: 24268212 Clinical Trial.
103 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page